Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III TrialRichard S. Finn, Baek‐Yeol Ryoo, Philippe Merle et al.|Journal of Clinical Oncology|2019Cited by 1.8k
Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trialJosep M. Llovet, Peiguo Cao, Ruocai Xu et al.|The Lancet Oncology|2023Cited by 436
Results of KEYNOTE-240: phase 3 study of pembrolizumab (Pembro) vs best supportive care (BSC) for second line therapy in advanced hepatocellular carcinoma (HCC).Richard S. Finn, Baek‐Yeol Ryoo, Philippe Merle et al.|Journal of Clinical Oncology|2019Cited by 210
Pembrolizumab (Pembro) therapy vs best supportive care (BSC) in advanced hepatocellular carcinoma (HCC): KEYNOTE-240Richard S. Finn, Ann‐Lii Cheng, Baek‐Yeol Ryoo et al.|Annals of Oncology|2019Cited by 11